Last updated: 11/27/2020 11:20:04
Study to evaluate antibody persistence in children previously vaccinated with Infanrix hexa™ or Infanrix-IPV/Hib™
EudraCT ID
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: Antibody persistence in children previously vaccinated with three doses of Infanrix hexa™ or Infanrix-IPV/Hib™
Trial description: The aim of this study is to assess antibody persistence in infants who received three doses of Infanrix hexa™ (DTPa-HBV-IPV/Hib) or Infanrix-IPV/Hib™ (DTPa-IPV/Hib) at 3, 5 and 11 months of age in study NCT00307034.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
None (Open Label)
Allocation:
Non-randomized
Primary outcomes:
Number of seroprotected subjects against anti-diphtheria (anti-D) and anti-tetanus (anti-T).
Timeframe: At Day 0
Concentrations of antibodies against anti-D and anti-T
Timeframe: At Day 0
Number of subjects with anti-pertussis toxoid (anti-PT), antifilamentous haemagglutinin (anti-FHA) and anti-pertactin (anti-PRN) antibody concentrations ≥5 ELISA units per milliliter (EL.U/mL).
Timeframe: At Day 0
Concentrations of antibodies against anti-PT, anti-FHA and anti-PRN.
Timeframe: At Day 0
Number of seroprotected subjects against anti-hepatitis B surface antigen (anti-HBs).
Timeframe: At Day 0
Concentrations of antibodies against anti-HBs.
Timeframe: At Day 0
Number of seroprotected subjects against anti-polyribosyl ribitol phosphate (anti-PRP).
Timeframe: At Day 0
Concentrations of antibodies against anti-PRP.
Timeframe: At Day 0
Number of subjects with serious adverse events (SAEs).
Timeframe: During the entire study period (up to Day 46)
Number of subjects with anti-HBs antibody concentrations ≥ 6.2 mIU/mL
Timeframe: At Day 0
Secondary outcomes:
Not applicable
Interventions:
Procedure/surgery: Blood Sampling
Enrollment:
58
Observational study model:
Not applicable
Primary completion date:
2011-15-07
Time perspective:
Not applicable
Clinical publications:
Silfverdal SA et al. (2014) Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age. Hum Vaccin Immunother. 10(10):2795-2798. doi: 10.4161/21645515.2014.970494.
Medical condition
Tetanus, Poliomyelitis, Haemophilus influenzae type b, acellular pertussis, Diphtheria, Hepatitis B, Diphtheria-Tetanus-aPertussis-Poliomyelitis-Haemophilus influenzae type b Vaccines
Product
SB213503, SB217744
Collaborators
Not applicable
Study date(s)
May 2011 to July 2011
Type
Interventional
Phase
4
Participation criteria
Sex
Female & Male
Age
5 - 6 years
Accepts healthy volunteers
Yes
- Subjects who had received 3 doses of Infanrix hexa™ or Infanrix-IPV/Hib™ in study NCT00307034.
- Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) LAR(s) can and will comply with the requirements of the protocol.
- Child in care.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
Inclusion and exclusion criteria
Inclusion criteria:
- Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) LAR(s) can and will comply with the requirements of the protocol.
- A male or female subject aged 5 years at the time of study entry.
- Written informed consent obtained from the parent(s)/LAR(s) of the subject.
- Healthy subjects as established by medical history and clinical examination before entering into the study.
Subjects who had received 3 doses of Infanrix hexa™ or Infanrix-IPV/Hib™ in study NCT00307034.
Exclusion criteria:
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
- Use of any investigational or non-registered product within 30 days prior to blood sampling.
- Evidence of previous or intercurrent diphtheria, tetanus, pertussis, polio, hepatitis B, and Hib vaccination or disease since the study NCT00307034, with the exception of hepatitis B vaccination in the DTPa-IPV/Hib group.
- Administration of immunoglobulins and/or any blood products within the 3 months prior to blood sampling.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- Family history of congenital or hereditary immunodeficiency.
Child in care.
Trial location(s)
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2011-15-07
Actual study completion date
2011-15-07
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website